Tilray Brands (TLRY) Cash & Current Investments (2017 - 2026)
Tilray Brands (TLRY) posted Cash & Current Investments of $60.2 million for Q1 2026, down 79.35% on a QoQ basis from $291.6 million in Q4 2025.
Tilray Brands (TLRY) Cash & Current Investments (2017 - 2026) Analysis & Trends
Tilray Brands' Cash & Current Investments history runs 10 years deep, the most recent figure standing at $60.2 million for Q1 2026.
- Quarterly Cash & Current Investments changed N/A year-over-year to $60.2 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $60.2 million (changed N/A YoY) and the FY2025 annual result came in at $34.7 million, down 86.68% from the prior year.
- Cash & Current Investments was $60.2 million for Q1 2026 at Tilray Brands, down from $291.6 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $490.6 million in Q3 2022 and bottomed at $34.7 million in Q2 2025.
- A 5-year average of $271.4 million and a median of $262.7 million in 2024 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2024 — Cash & Current Investments soared 56.34% — and 2025, when it tumbled 86.68%.
- Tilray Brands' Cash & Current Investments stood at $433.5 million in 2022, then plunged by 40.07% to $259.8 million in 2023, then dropped by 2.9% to $252.2 million in 2024, then grew by 15.58% to $291.6 million in 2025, then slumped by 79.35% to $60.2 million in 2026.
- Business Quant data shows TLRY's Cash & Current Investments at $60.2 million in Q1 2026, $291.6 million in Q4 2025, and $264.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.60 Bn | 12.18 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Tilray Brands | 452.95 Mn | 392.75 Mn | 54.95 Mn | 60.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 60.20 Mn |
| Nov 30, 2025 | 291.55 Mn |
| Aug 31, 2025 | 264.83 Mn |
| May 31, 2025 | 34.70 Mn |
| Nov 30, 2024 | 252.25 Mn |
| Aug 31, 2024 | 280.06 Mn |
| May 31, 2024 | 260.52 Mn |
| Feb 29, 2024 | 225.86 Mn |
| Nov 30, 2023 | 259.79 Mn |
| Aug 31, 2023 | 179.13 Mn |
| May 31, 2023 | 206.63 Mn |
| Feb 28, 2023 | 408.28 Mn |
| Nov 30, 2022 | 433.50 Mn |
| Aug 31, 2022 | 490.64 Mn |
| May 31, 2022 | 415.91 Mn |
| Feb 28, 2022 | 279.21 Mn |
| Nov 30, 2021 | 331.78 Mn |
| Aug 31, 2021 | 376.30 Mn |
| May 31, 2021 | 488.47 Mn |
| May 31, 2020 | 360.65 Mn |